All Posts by

Chris Velasquez

Believe in You: Cancer Survivors Train for the Dolphins Cancer Challenge

When Karen Wilford first battled breast cancer in 2008, her doctors ordered chemotherapy, radiation and surgery. She remembers being told she’d lose her hair and was given a wig and makeup to help her feel better. Things were noticeably different when the cancer returned as stage 4 a few years ago.

Purpose Beyond a Cure: Advancing Hodgkin Lymphoma Treatment

Emilie Lynch has passed the 5-year milestone that doctors consider a yardstick for being cured of Hodgkin lymphoma not once but three times. Today, she channels her experience into a career as a clinical pharmacy specialist at UF Health.

Biological Age as a Tool to Predict Early-Onset Colorectal Cancer Risk

Recent research has established a connection between a person’s “biological age” and their risk of developing colon polyps, which are known to be a risk factor for colorectal cancer. Biological age can be measured through various tests and reflects the impacts of lifestyle choices, genetics and environmental factors on an individual’s body. Unlike chronological age, which simply counts the years a person has lived, biological age is based on physiological markers.

Dozens of Presentations Advance Multiple Myeloma Research at the American Society for Hematology Meeting

Patients with multiple myeloma are living longer, healthier lives thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease, the second most common blood cancer. “We’d like to develop a curative treatment for multiple myeloma, and we are at the point where that’s possible,” said C. Ola Landgren, M.D., Ph.D., who leads the Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma

There’s good news on the treatment horizon for two typically slow-growing versions of lymphoma: follicular lymphoma and marginal zone lymphoma. Research presented by physicians from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, at the American Society of Hematology’s 2024 meeting in San Diego describes positive results for the antibody drug loncastuximab tesirine (Zynlonta) in patients with high-risk forms of these two blood cancers.

Mayo Clinic Minute: Detecting pancreatic cancer

Approximately 66,000 people in the U.S. will be diagnosed with pancreatic cancer this year, according to the National Cancer Institute. Dr. Michael Wallace, a gastroenterologist at Mayo Clinic, warns that early signs of this deadly disease are easy to miss.

Sylvester Logo